Locally acting ACE-083 increases muscle volume in healthy volunteers.

about

Locally acting ACE-083 increases muscle volume in healthy volunteers.

Item

http://www.wikidata.org/entity/Q52682865

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

Locally acting ACE-083 increases muscle volume in healthy volunteers.

@en

Locally acting ACE-083 increases muscle volume in healthy volunteers.

@nl

type

Item

label

Locally acting ACE-083 increases muscle volume in healthy volunteers.

@en

Locally acting ACE-083 increases muscle volume in healthy volunteers.

@nl

prefLabel

Locally acting ACE-083 increases muscle volume in healthy volunteers.

@en

Locally acting ACE-083 increases muscle volume in healthy volunteers.

@nl

P1476

Locally acting ACE-083 increases muscle volume in healthy volunteers.

@en

P2093

Barry Miller

http://www.w3.org/2001/XMLSchema#string

Chad E Glasser

http://www.w3.org/2001/XMLSchema#string

Dawn Wilson

http://www.w3.org/2001/XMLSchema#string

Kenneth M Attie

http://www.w3.org/2001/XMLSchema#string

Matthew L Sherman

http://www.w3.org/2001/XMLSchema#string

Michael R Gartner

http://www.w3.org/2001/XMLSchema#string

P2860

A phase I/IItrial of MYO-029 in adult subjects with muscular dystrophy

MRI biomarker assessment of neuromuscular disease progression: a prospective observational cohort study.

Activin A more prominently regulates muscle mass in primates than does GDF8.

Treatment of sporadic inclusion body myositis with bimagrumab

Biochemistry and Biology of GDF11 and Myostatin: Similarities, Differences, and Questions for Future Investigation

Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease.

Distinct disease phases in muscles of facioscapulohumeral dystrophy patients identified by MR detected fat infiltration

Myostatin antibody (LY2495655) in older weak fallers: a proof-of-concept, randomised, phase 2 trial.

Myostatin inhibitor ACE-031 treatment of ambulatory boys with Duchenne muscular dystrophy: Results of a randomized, placebo-controlled clinical trial.

P304

921-926

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1002/MUS.26113

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-03-15T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29486514

http://www.w3.org/2001/XMLSchema#string

P932

5969095

http://www.w3.org/2001/XMLSchema#string